- ¥1113 - 21245
- Solarbio
- 北京
- P00970
- 2026年08月13日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
阿拉丁试剂，充足现货，稳定批间差Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保质期：
Upon receipt, store it immediately at -70°C or lower for long term storage. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: <br>2-8°C for 2-7 days; <br>-20°C for 1 months and -70℃ for 3 months.
- 保存条件：
Upon receipt, store it immediately at -70°C or lower for long term storage. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: <br>2-8°C for 2-7 days; <br>-20°C for 1 months and -70℃ for 3 months.
- 英文名：
Factor IX
- 库存：
999
- 供应商：
北京索莱宝科技有限公司
- 规格：
10ug/50ug/500ug/1mg
| 规格： | 10ug | 产品价格： | ¥1113 |
|---|---|---|---|
| 规格： | 50ug | 产品价格： | ¥2725 |
| 规格： | 500ug | 产品价格： | ¥14909 |
| 规格： | 1mg | 产品价格： | ¥21245 |
| 基因名 | Factor IX |
| 别名 | F9; Coagulation factor IX; Christmas factor; Plasma thromboplastin component; Coagulation factor IXa light chain; Coagulation factor IXa heavy chain |
| 蛋白号 | P00740 |
| 种属 | Human |
| 宿主 | HEK293 |
| 产品描述 | Recombinant Human Coagulation Factor IX is produced by our Mammalian expression system and the target gene encoding Thr29-Thr461 is expressed with a 6His tag at the C-terminus. |
| 区间范围 | Thr29-Thr461 |
| 标签信息 | C-6His |
| 预测分子量 | 60-90 kDa |
| 表观分子量 | 60-90 KDa, reducing conditions |
| 纯度 | ≥95% by SDS‐PAGE. |
| 内毒素 | <1EU/ug as determined by LAL test. |
| 溶剂 | Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 10% Glycerol, pH 8.0. |
| 复溶 | Reconstituted protein solution can be diluted with distilled water. Always centrifuge tubes before opening. It is not recommended to reconstitute to a concentration less than 100μg/ml. |
| 储存条件 | Upon receipt, store it immediately at -70°C or lower for long term storage. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: 2-8°C for 2-7 days; -20°C for 1 months and -70℃ for 3 months. |
| 运输条件 | 干冰运输（需要收取干冰费） |
| 背景说明 | Coagulation factor IX（F9), is a member of the peptidase S1 family. It contains two EGF-like domains, a Gla domain and a peptidase S1 domain. It is primarily expressed in the liver and secreted in plasma. Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa. Mutations in position 43 and 46 prevents cleavage of the propeptide, mutation in position 93 probably fails to bind to cell membranes, mutation in position 191 or in position 226 prevent cleavage of the activation peptide. Mutations of human F9 can result in thrombophilia and recessive X-linked hemophilia B (HEMB). An X-linked blood coagulation disorder characterized by a permanent tendency to hemorrhage, due to factor IX deficiency. It is phenotypically similar to hemophilia A, but patients present with fewer symptoms. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. |
| 细胞活性 | No activity experimental data, to be verified. |
| ELISA活性 | No activity experimental data, to be verified. |
| SPR/BLI活性 | No activity experimental data, to be verified. |
| 研究领域 | 生物制药相关研究 |
| 英文名称 | Factor IX |
| 中文名称 | Factor IX蛋白 |
| 单位 | 支 |
| 规格 | 10ug ; 50ug ; 500ug ; 1mg |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Factor IX Gene Therapy for Hemophilia
Using gene therapy to produce systemic levels of human factor IX for the treatment of hemophilia B has been clinically evaluated using viral-based vectors. The efficacy of this approach has been limited because of immune responses
Secretion of Recombinant Human Insulin-Like Growth Factor I (IGF-I)
The development of efficient recombinant protein production processes can be a critical factor in whether or not a pharmaceutical therapeutic protein can enter human clinical trials and ultimately the marketplace. This is especially true
Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B
Hemophilia B is an X-linked genetic disorder that typically results from chronic circulating deficiency of blood coagulation factor IX (FIX) (1). While the occurrence of hemophilia B is significantly less frequent than hemophilia A (factor
技术资料暂无技术资料 索取技术资料
